Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Zontivity vorapaxar: Additional Phase III data

    Merck & Co. Inc.(NYSE:MRK), Whitehouse Station, N.J. Product: Zontivity vorapaxar (MK-5348) (formerly SCH 530348) Business: Cardiovascular Molecular target: Protease-activated receptor 1 (PAR1); Thrombin receptor …

    Published on 3/2/2015
  • Alpha galactosidase: Interim Phase I/II data

    Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX), Carmiel, Israel Product: Alpha galactosidase (PRX-102) Business: Endocrine/Metabolic Molecular target: Alpha galactosidase A Description: Plant cell-expressed …

    Published on 2/23/2015
  • BAX 335: Interim Phase I/II data

    Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: BAX 335 Business: Hematology Molecular target: NA Description: Adeno-associated virus vector-based gene therapy that provides a mechanism for the patients …

    Published on 2/23/2015
  • Brincidofovir: Additional Phase III data

    Chimerix Inc. (NASDAQ:CMRX), Durham, N.C. Product: Brincidofovir (CMX001) Business: Infectious Molecular target: NA Description: Oral lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations …

    Published on 2/23/2015
  • Daliresp roflumilast: Phase III/IV data

    Actavis plc (NYSE:ACT), Dublin, Ireland Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Daliresp roflumilast (DaxasEU) (APTA-2217) Business: …

    Published on 2/23/2015
  • Eylea aflibercept ophthalmic solution: Additional Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Eylea aflibercept ophthalmic solution (VEGF Trap-Eye) Business: Ophthalmic Molecular target: Vascular …

    Published on 2/23/2015
  • GLPG1690: Phase I data

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: GLPG1690 Business: Pulmonary Molecular target: NA Description: Undisclosed compound Indication: …

    Published on 2/23/2015
  • Imbruvica ibrutinib: Clinical trial data

    Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Imbruvica ibrutinib (PCI-32765) Business: Cancer Molecular target: Brutons tyrosine kinase (Btk) Description…

    Published on 2/23/2015
  • Imbruvica ibrutinib: Clinical trial data

    Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Imbruvica ibrutinib (PCI-32765) Business: Cancer Molecular target: Brutons tyrosine kinase (Btk) Description…

    Published on 2/23/2015
  • Imbruvica ibrutinib: Phase Ib data

    Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif. Product: Imbruvica ibrutinib (PCI-32765) Business: Transplant Molecular target: Brutons tyrosine kinase (Btk) Description: Brutons tyrosine kinase (Btk) inhibitor that…

    Published on 2/23/2015
  • Locilex pexiganan acetate: Phase I data

    Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX), New York, N.Y. Product: Locilex pexiganan acetate (formerly Cytolex, MSI-78) Business: Infectious Molecular target: NA Description: 22-amino acid linear peptide with ability …

    Published on 2/23/2015
  • Motesanib diphosphate: Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Motesanib diphosphate (AMG 706) Business: Cancer Molecular target: Vascular endothelial growth factor (…

    Published on 2/23/2015
  • MRX6: Phase II data

    Celsus Therapeutics plc (NASDAQ:CLTX), London, U.K. Product: MRX6, MRX-6 Business: Dermatology Molecular target: Phospholipase A2 (PLA2) Description: Topical multifunctional anti-inflammatory compound that inhibits …

    Published on 2/23/2015
  • Olipudase alfa: Phase Ib data

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Olipudase alfa (GZ402665) Business: Endocrine/Metabolic Molecular target: NA Description: Recombinant human acid sphingomyelinase (rhASM) Indication: Treat Niemann…

    Published on 2/23/2015
  • Oral semaglutide: Phase II data

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Oral semaglutide (OG217SC, NN9924) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) Description: Oral …

    Published on 2/23/2015
  • Ornithine phenylacetate: Phase IIa data

    Ocera Therapeutics Inc. (NASDAQ:OCRX), Palo Alto, Calif. Product: Ornithine phenylacetate (OCR-002) Business: Hepatic Molecular target: NA Description: Ammonia scavenger Indication: Treat upper gastrointestinal bleeding…

    Published on 2/23/2015
  • VB-201: Phase II data

    VBL Therapeutics Ltd. (NASDAQ:VBLT), Or Yehuda, Israel Product: VB-201 Business: Autoimmune Molecular target: Toll-like receptor 2 (TLR2); Toll-like receptor 4 (TLR4) Description: Toll-like receptor 2 (TLR2) and TLR4 …

    Published on 2/23/2015
  • VB-201: Phase II data

    VBL Therapeutics Ltd. (NASDAQ:VBLT), Or Yehuda, Israel Product: VB-201 Business: Autoimmune Molecular target: Toll-like receptor 2 (TLR2); Toll-like receptor 4 (TLR4) Description: Toll-like receptor 2 (TLR2) and TLR4 …

    Published on 2/23/2015
  • ACH-3102: Additional Phase II data

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: ACH-3102 Business: Infectious Molecular target: HCV NS5A protein Description: Pan-genotypic, second-generation HCV NS5A protein inhibitor …

    Published on 2/16/2015
  • ALKS 8700: Phase I data

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: ALKS 8700 Business: Autoimmune Molecular target: NA Description: Small molecule prodrug of monomethyl fumarate (MMF) Indication: Treat multiple sclerosis (MS) …

    Published on 2/16/2015
  • Amigal migalastat: Additional Phase III data

    Amicus Therapeutics Inc. (NASDAQ:FOLD), Cranbury, N.J. Product: Amigal migalastat (AT1001) Business: Endocrine/Metabolic Molecular target: Alpha galactosidase A Description: Small molecule that enhances alpha …

    Published on 2/16/2015
  • Biosimilar adalimumab: Phase I data

    Oncobiologics Inc., Cranbury, N.J. Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521), Zhejiang, China Product: Biosimilar adalimumab (ONS-3010) Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) …

    Published on 2/16/2015
  • Cariprazine: Phase III data

    Actavis plc (NYSE:ACT), Dublin, Ireland Gedeon Richter Ltd. (Budapest:RICHTER), Budapest, Hungary Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Product: Cariprazine (RGH-188, MP-214) Business: Neurology …

    Published on 2/16/2015
  • DRM04: Phase IIb data

    Dermira Inc. (NASDAQ:DERM), Redwood City, Calif. Product: DRM04 Business: Other Molecular target: NA Description: Topical anticholinergic agent Indication: Treat severe primary axillary hyperhidrosis Endpoint: …

    Published on 2/16/2015
  • EG-1962: Interim Phase I/II data

    Edge Therapeutics Inc., New Providence, N.J. Product: EG-1962 Business: Neurology Molecular target: Calcium channel Description: Sustained-release injectable formulation of nimodipine, a generic calcium channel blocker,…

    Published on 2/16/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993